Back

Analysis of whole genome sequence data shows association of Alzheimer's disease with rare coding variants in ABCA7, PSEN1, SORL1 and TREM2

Curtis, D.; Joseph, S.; The Alzheimer Disease Neuroimaging Initiative,

2025-07-27 psychiatry and clinical psychology
10.1101/2025.07.27.25332260
Show abstract

Previous studies have reported associations between risk of Alzheimers disease (AD) or dementia and rare coding variants in a number of genes. A two stage strategy was used in which a previously released whole exome sequenced sample was used to prioritise 100 genes showing the strongest evidence for association with AD. These genes were then analysed in a newly released whole genome sequenced sample to identify those which showed statistically significant evidence for rare coding variant association. Association analysis of loss of function (LOF) and nonsynonymous variants was carried out in 18,998 protein coding genes using 11,188 controls and 5,808 cases, with nonsynonymous variants being annotated using 45 different pathogenicity predictors. The 100 genes showing strongest evidence for association were then analysed in a new sample of 27,749 controls and 13,234 cases using only the pathogenicity predictor which had performed best in the first sample. Four genes were statistically significant after correction for multiple testing: ABCA7, PSEN1, SORL1 and TREM2. The association of different categories of variant with AD was characterised and the pattern was seen to vary between genes. This study quantifies the contribution of different types of variant within each gene to AD risk. In general these variants are probably too rare to be clinically useful for assessing individual risk of AD. Further research into the mechanisms whereby the products of these genes affect AD pathogenesis may aid development of novel therapeutic strategies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Alzheimer's & Dementia: Translational Research & Clinical Interventions
based on 13 papers
Top 0.1%
15.7%
2
Molecular Psychiatry
based on 84 papers
Top 0.7%
7.7%
3
Nature Communications
based on 483 papers
Top 10%
7.7%
4
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
based on 28 papers
Top 0.7%
6.5%
5
PLOS ONE
based on 1737 papers
Top 66%
5.4%
6
Alzheimer's & Dementia
based on 84 papers
Top 3%
4.6%
7
Translational Psychiatry
based on 94 papers
Top 4%
4.6%
50% of probability mass above
8
Alzheimer's Research & Therapy
based on 31 papers
Top 2%
4.6%
9
Scientific Reports
based on 701 papers
Top 50%
3.0%
10
Nature Genetics
based on 72 papers
Top 4%
2.9%
11
Neurobiology of Aging
based on 29 papers
Top 1%
2.5%
12
Frontiers in Genetics
based on 32 papers
Top 2%
1.8%
13
Journal of Neurology, Neurosurgery & Psychiatry
based on 26 papers
Top 3%
1.8%
14
Journal of Alzheimer’s Disease
based on 23 papers
Top 2%
1.6%
15
Brain Communications
based on 79 papers
Top 5%
1.6%
16
Cells
based on 14 papers
Top 0.9%
1.4%
17
Nature Medicine
based on 88 papers
Top 12%
1.2%
18
Genome Medicine
based on 56 papers
Top 6%
0.8%
19
Proceedings of the National Academy of Sciences
based on 100 papers
Top 11%
0.8%
20
Brain, Behavior, and Immunity
based on 35 papers
Top 3%
0.8%
21
Brain
based on 69 papers
Top 7%
0.8%
22
Communications Biology
based on 36 papers
Top 4%
0.8%
23
Biological Psychiatry Global Open Science
based on 23 papers
Top 3%
0.8%
24
NeuroImage: Clinical
based on 77 papers
Top 7%
0.8%
25
Journal of Alzheimer's Disease
based on 31 papers
Top 3%
0.8%
26
Acta Neuropsychiatrica
based on 11 papers
Top 2%
0.7%
27
eLife
based on 262 papers
Top 34%
0.7%